TAS-102 for Colorectal Cancer
Study of TAS-102 Plus Radiation Therapy for the Treatment of the Liver in Patients With Hepatic Metastases From Colorectal Cancer
See full descriptionAbout the trial for Colorectal Cancer
Treatment Groups
This trial involves 2 different treatments. TAS-102 is the primary treatment being studied. Participants will all receive the same treatment. There is no placebo group. The treatments being tested are in Phase 1 & 2 and have already been tested with other people.
About The Treatment
Eligibility
This trial is for patients born any sex aged 18 and older. There are 10 eligibility criteria to participate in this trial as listed below.
Approximate Timelines
Measurement Requirements
This trial is evaluating whether TAS-102 will improve 2 primary outcomes and 5 secondary outcomes in patients with Colorectal Cancer. Measurement will happen over the course of Baseline, 1 month post treatment, every 6 months for two years or until death.
Who is running the study
Principal InvestigatorPatient Q & A Section
What are the signs of colorectal cancer?
Signs of [colorectal cancer](https://www.withpower.com/clinical-trials/colorectal-cancer) involve loss of stool in stools, black stools of unknown cause, or blood in stools, and may be detectable through examination or through cancer screening. The presence of weight loss in more than 30% of people with colorectal cancer suggests that further investigation is warranted. Although colorectal cancer screening may not solve the problem of cancer, it may decrease the impact of colorectal cancer on deaths, especially for cancers with early signs but less than the maximum life expectancies.
What is colorectal cancer?
In developed countries, colorectal cancer incidence is rising. This may be attributed to increasing use of colonoscopy, increasing age, increased body mass index, and increased consumption of processed white meat (meat dishes and sauces). To reduce the burden of this disease, screening programmes that target the older and overweight population may be effective. Preventive strategies targeting colorectal cancer should take the socioeconomic aspect of the population into consideration.
Can colorectal cancer be cured?
A cure for CRC isn't feasible. A cure implies a cure or a cure: a cure (even if it is possible) doesn't imply cure. That cure is possible for most people with CRC who have been carefully managed according to published clinical guidelines. No one has yet described a cure for CRC with a completely new drug and that cure is only possible for some people. A cure implies a cure for a cure and cure for a cure. A cure with cure means cure. For example, a cure for cure means a cure for cure for cure (treat) a cure for cure.
What are common treatments for colorectal cancer?
Many colorectal cancer patients present for treatment with palliative care, most commonly by chemotherapy, including 5-fluorouracil, irinotecan, oxaliplatine, and oxaliplatin. Colorectal cancer is also often treated with radiation therapy or surgery. Some patients with colorectal cancer are candidates for curative surgery, but in the vast majority, patients are subjected to palliative treatment, such as chemotherapy, radiation therapy, or surgery. Palliative treatment may be provided in an inpatient or outpatient setting. Other treatment is for symptoms, such as bowel obstruction, anal fissures, and blood in the stool.
How many people get colorectal cancer a year in the United States?
Overall, there is variation among states in the incidence of colorectal cancer. Although the absolute risk is 1.1 per 100,000 for blacks and whites, the absolute risk per year for black men and white women is less than 0.7 percent. To reduce the number of cases occurring yearly, the incidence of colorectal cancer should be reduced in blacks and reduced in whites.
What causes colorectal cancer?
Several cancers can cause colorectal cancer; they include [ulcerative colitis](https://www.withpower.com/clinical-trials/ulcerative-colitis), familial adenomatous polyposis and Li-Fraumeni syndrome. Risk factors for colorectal cancer include: a history of chronic colitis or Crohn's disease; being overweight and tobacco use. A history of colorectal cancer and advanced age are associated increased colorectal cancer incidence. An increased risk of colorectal cancer was observed in siblings of those who had colorectal cancer. The risk of colorectal cancer was reduced in first-degree relatives.
What is the average age someone gets colorectal cancer?
It is important to differentiate the average age the cancer is diagnosed from the first symptoms. Symptoms usually occur earlier (about 5-10 years) than a mass or lesion on a colonoscopy and CT scan. Symptoms occur so frequently that an individual may have several lesions or masses that occur over an extended period of time (months to years). Most colorectal cancers are diagnosed after they have become debilitating. Symptoms of colorectal cancer are common in elderly people, with about 1 in 5 diagnosed after they are 80. The average age of diagnosis for colorectal cancer is 70. Many colorectal cancers were diagnosed over the years for individuals who were not currently symptomatic.
Has tas-102 proven to be more effective than a placebo?
• Overall, there were no differences between the 2 treatments at 6 months. • The majority of patients had a very good clinical benefit and were able to stop the therapy. • Tas-102 has proved to be more effective than a placebo in a Phase III study of patients with advanced cancer. • The benefits were measured by the following parameters: time to first progression (TTP), progression-free survival (PFS), overall survival (OS) and tumor-related toxicity. • No significant difference between the 2 treatment groups was found for TTP, OS and tumor-related complications. • TTP was 12.2 weeks less than the placebo treatment (P=0.01) (hazard ratio 0.40) and PFS was 13.
Does tas-102 improve quality of life for those with colorectal cancer?
The use of Tas-102 was safe and associated with improvement in some aspects of HR-QOL. The use of Tas-102 during chemotherapy might be helpful in some patients.
Does colorectal cancer run in families?
There is a familial tendency in CRC, but this tends not be related to the genetic factors known for familial adenomatous polyposis. Because familial polyposis predisposes to other cancers, this might indicate that the genetic predisposition does not trigger CRC but the presence of familial polyposis increases the lifetime probability that CRC will develop.
What are the common side effects of tas-102?
The use of tas-102 is associated with severe, often permanent side effects that need to be considered. These side effects tend to manifest themselves during the first 2 months of therapy. They are related to increased dosages or duration of tas-102 therapy - not due to cumulative exposure or cumulative dose.
Have there been any new discoveries for treating colorectal cancer?
It is clear that we have made a number of improvements in treating colorectal cancer. There are a number of exciting developments relating to colonoscopy and its use in colon cancer detection and the treatment of colorectal cancer. Unfortunately these developments are not available to all of us and the treatment of colorectal cancer has not been simplified to a point where we know the best treatment plan for all patients. However, there is a good possibility that these new methods of treatment will be accepted and the incidence of colorectal cancer will start to fall quickly and, ultimately, colorectal cancer should be treated more easily.